DeutschNewstral
Article
bizjournals.com on 2017-08-01 23:21
Bedford’s Ocular Therapeutix turns to layoffs after FDA rejection
Related news
- Under SEC scrutiny, Bedford’s Ocular Therapeutix plans FDA do-overbizjournals.com
- Ocular Therapeutix replaces regulatory chief after FDA rejectionbizjournals.com
- Cambridge's Akcea discloses layoffs after FDA drug rejectionbizjournals.com
Attention turns to phase 2 of Bedford’s Boys Ranch ParkStar Telegram- MOcular Therapeutix shares rally after company submits FDA amendmentmarketwatch.com
- Ocular Therapeutix faces fraud allegations as FDA rejects eye drugbizjournals.com
- MKala stock declines 6% after FDA approves ocular surgery productmarketwatch.com
- MOcular Therapeutix stock drops 10% after FDA warning lettermarketwatch.com
- Cempra's stock down over FDA rejectionbizjournals.com
- Austin drugmaker's stock falters after latest FDA rejectionbizjournals.com
- TransEnterix raised $26M leading up to FDA rejectionbizjournals.com
- FDA warned Intarcia about manufacturing issues before drug rejectionbizjournals.com
- BAcadia Is Hit by Wave of Downgrades After FDA Rejectionbarrons.com
- Following FDA rejection, Akebia lays off 180 workersbizjournals.com
- FFDA arthritis drug rejection hits Eli Lilly sharesft.com
- Acer Therapeutics stock plummets 80 percent on FDA rejectionbizjournals.com
- Alkermes blames drug rejection on Covid halting FDA inspectionsbizjournals.com
- Drugmaker with new Waltham offices vows to fight FDA rejectionbizjournals.com
- MOcular stock drops 7% after eye pain drug fails to get FDA approvalmarketwatch.com
- MOcular Therapeutix shares plummet after FDA pushes back on eye-drug approvalmarketwatch.com